264 related articles for article (PubMed ID: 2307371)
1. The block to transcription elongation is promoter dependent in normal and Burkitt's lymphoma c-myc alleles.
Spencer CA; LeStrange RC; Novak U; Hayward WS; Groudine M
Genes Dev; 1990 Jan; 4(1):75-88. PubMed ID: 2307371
[TBL] [Abstract][Full Text] [Related]
2. The intron enhancer of the immunoglobulin kappa gene activates c-myc but does not induce the Burkitt-specific promoter shift.
Polack A; Strobl L; Feederle R; Schweizer M; Koch E; Eick D; Wiegand H; Bornkamm GW
Oncogene; 1991 Nov; 6(11):2033-40. PubMed ID: 1945409
[TBL] [Abstract][Full Text] [Related]
3. Absence of a paused transcription complex from the c-myc P2 promoter of the translocation chromosome in Burkitt's lymphoma cells: implication for the c-myc P1/P2 promoter shift.
Strobl LJ; Kohlhuber F; Mautner J; Polack A; Eick D
Oncogene; 1993 Jun; 8(6):1437-47. PubMed ID: 8502472
[TBL] [Abstract][Full Text] [Related]
4. The block of elongation in c-myc exon 1 is abolished in Burkitt's lymphoma cell lines with variant translocation.
Eick D; Polack A; Kofler E; Bornkamm GW
Oncogene; 1988 Oct; 3(4):397-403. PubMed ID: 3078949
[TBL] [Abstract][Full Text] [Related]
5. Molecular analysis of the c-myc transcription elongation block. Implications for the generation of Burkitt's lymphoma.
Spencer CA; Groudine M
Ann N Y Acad Sci; 1990; 599():12-28. PubMed ID: 2221669
[No Abstract] [Full Text] [Related]
6. NF-kappa B activity is required for the deregulation of c-myc expression by the immunoglobulin heavy chain enhancer.
Kanda K; Hu HM; Zhang L; Grandchamps J; Boxer LM
J Biol Chem; 2000 Oct; 275(41):32338-46. PubMed ID: 10931834
[TBL] [Abstract][Full Text] [Related]
7. Identification of a locus control region in the immunoglobulin heavy-chain locus that deregulates c-myc expression in plasmacytoma and Burkitt's lymphoma cells.
Madisen L; Groudine M
Genes Dev; 1994 Sep; 8(18):2212-26. PubMed ID: 7958890
[TBL] [Abstract][Full Text] [Related]
8. Expression of P0- and P3-RNA from the normal and translocated c-myc allele in Burkitt's lymphoma cells.
Eick D; Polack A; Kofler E; Lenoir GM; Rickinson AB; Bornkamm GW
Oncogene; 1990 Sep; 5(9):1397-402. PubMed ID: 2216463
[TBL] [Abstract][Full Text] [Related]
9. Regulatory elements in the immunoglobulin kappa locus induce c-myc activation and the promoter shift in Burkitt's lymphoma cells.
Polack A; Feederle R; Klobeck G; Hörtnagel K
EMBO J; 1993 Oct; 12(10):3913-20. PubMed ID: 8404859
[TBL] [Abstract][Full Text] [Related]
10. Allele-specific activation of the c-myc gene in an atypical Burkitt's lymphoma carrying the t(2;8) chromosomal translocation 250 kb downstream from c-myc.
Tachibana K; Takayama N; Matsuo K; Kato S; Yamamoto K; Ohyama K; Umezawa A; Takano T
Gene; 1993 Feb; 124(2):231-7. PubMed ID: 8444346
[TBL] [Abstract][Full Text] [Related]
11. Expression of normal and translocated c-myc alleles in Burkitt's lymphoma cells: evidence for different regulation.
Eick D; Bornkamm GW
EMBO J; 1989 Jul; 8(7):1965-72. PubMed ID: 2551669
[TBL] [Abstract][Full Text] [Related]
12. The role of immunoglobulin kappa elements in c-myc activation.
Hörtnagel K; Mautner J; Strobl LJ; Wolf DA; Christoph B; Geltinger C; Polack A
Oncogene; 1995 Apr; 10(7):1393-401. PubMed ID: 7731690
[TBL] [Abstract][Full Text] [Related]
13. Sequences in the human c-myc P2 promoter affect the elongation and premature termination of transcripts initiated from the upstream P1 promoter.
Meulia T; Krumm A; Spencer C; Groudine M
Mol Cell Biol; 1992 Oct; 12(10):4590-600. PubMed ID: 1406649
[TBL] [Abstract][Full Text] [Related]
14. NF-kappa B sites function as positive regulators of expression of the translocated c-myc allele in Burkitt's lymphoma.
Ji L; Arcinas M; Boxer LM
Mol Cell Biol; 1994 Dec; 14(12):7967-74. PubMed ID: 7969136
[TBL] [Abstract][Full Text] [Related]
15. A Myc-associated zinc finger protein-related factor binding site is required for the deregulation of c-myc expression by the immunoglobulin heavy chain gene enhancers in Burkitt's lymphoma.
Hu HM; Arcinas M; Boxer LM
J Biol Chem; 2002 Mar; 277(12):9819-24. PubMed ID: 11777933
[TBL] [Abstract][Full Text] [Related]
16. Effect of somatic mutation within translocated c-myc genes in Burkitt's lymphoma.
Rabbitts TH; Forster A; Hamlyn P; Baer R
Nature; 1984 Jun 14-20; 309(5969):592-7. PubMed ID: 6547209
[TBL] [Abstract][Full Text] [Related]
17. Deregulation of the proto-oncogene c-myc through t(8;22) translocation in Burkitt's lymphoma.
Gerbitz A; Mautner J; Geltinger C; Hörtnagel K; Christoph B; Asenbauer H; Klobeck G; Polack A; Bornkamm GW
Oncogene; 1999 Mar; 18(9):1745-53. PubMed ID: 10208435
[TBL] [Abstract][Full Text] [Related]
18. Activation of the c-myc p1 promoter in Burkitt's lymphoma by the hs3 immunoglobulin heavy-chain gene enhancer.
Hu HM; Kanda K; Zhang L; Boxer LM
Leukemia; 2007 Apr; 21(4):747-53. PubMed ID: 17287852
[TBL] [Abstract][Full Text] [Related]
19. The c-MYC allele that is translocated into the IgH locus undergoes constitutive hypermutation in a Burkitt's lymphoma line.
Bemark M; Neuberger MS
Oncogene; 2000 Jul; 19(30):3404-10. PubMed ID: 10918597
[TBL] [Abstract][Full Text] [Related]
20. Somatic mutation and transcriptional deregulation of myc in endemic Burkitt's lymphoma disease: heptamer-nonamer recognition mistakes?
Morse B; South VJ; Rothberg PG; Astrin SM
Mol Cell Biol; 1989 Jan; 9(1):74-82. PubMed ID: 2927398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
